Data Presented at IDWeek Highlight Risk Factors for Carbapenem Resistance Among Patients Hospitalized for Serious Infections

Saturday, October 29, 2016 Research News
Email Print This Page Comment bookmark
Font : A-A+

DUBLIN, Oct. 29, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company committed to research

informing the treatment of infectious diseases, presented new data identifying hospitalized patients with serious infections due to Enterobactericaeae who are at greater risk for having carbapenem-resistant Enterobacteriaceae (CRE) infections. Results
were presented today at IDWeek 2016 in New Orleans.

Logo -

The prevalence of hospital-onset infections due to CRE has increased in recent years.1 As such, the Centers for Disease Control and Prevention (CDC) has identified CRE as one of the three most urgent public health threats.1 CRE has been attributed to approximately 9,000 healthcare-associated infections per year, with 600 deaths per year resulting from the two most common types of CRE, carbapenem-resistant Klebsiella species and carbapenem-resistant Escherichia coli (E. coli).1

"The increasing prevalence of difficult-to-treat infections—including those caused by CRE— represents a significant challenge to physicians, as certain Gram-negative bacteria have become resistant to nearly all treatments currently available for patients," said David Nicholson, Ph.D, Chief R&D Officer, Allergan. "These results are an important addition to the growing body of knowledge for the healthcare community on how to make empiric treatment decisions for these patients."

"This research is a testament to Allergan's commitment to investing in the clinical and health outcomes research needed to better understand and treat serious infections caused by pathogens of greatest concern," Nicholson said.

The study, given as an oral presentation titled, "Identification of Patients at Greatest Risk for Carbapenem Resistance in Patients with Serious Hospital-Onset Infections Due to Enterobacteriaceae Species," evaluated 10,634 U.S. hospitalized patients in the Premier hospital database between January 2011 and December 2014 with invasive hospital-onset infections due to Enterobacteriaceae. The overall prevalence of CRE in this total population was 4.5% (481/10,634). Enterobacteriaceae were considered carbapenem-resistant if documented as nonsusceptible to meropenem, imipenem, doripenem or ertapenem.

Results from this retrospective, observational study found that factors associated with increased risk of CRE included the following:

  • >2% baseline prevalence of CRE in the hospital where patient is admitted
  • Receipt of dialysis in current hospital admission
  • Evidence of an infection in the three months prior to current hospital admission
  • Cumulative number of prior antibiotic exposure in current or previous hospital admission

"Physicians in the hospital setting are under pressure to quickly act when evaluating and determining appropriate treatment options for admitted patients with serious infections," said Tom Lodise, PharmD, Ph.D, Albany College of Pharmacy and Health Sciences and lead investigator of the study. "These data are critically important for healthcare professionals prioritizing new information on CRE prevalence and risk factors associated with the probability of a CRE infection."

About Gram-Negative Infections

Gram-negative bacteria are highly adaptive pathogens that can develop resistance through several mechanisms and can pass along genetic materials that allow other bacteria to become drug-resistant as well.

According to the Centers for Disease Control and Prevention (CDC), rates of Klebsiella pneumoniae carbapenemase (KPC) producing organisms in particular have increased across the country significantly in the past 10 years. In addition, E. coli, Klebsiella (K. pneumoniae and K. oxytoca) and Pseudomonas aeruginosa resistance are on the rise.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma.  Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care.  This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.

Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life.  Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

1 Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention website. Accessed September 22, 2016.


Investors: Lisa DeFrancesco  (862) 261-7152

Media: Mark Marmur(862) 261-7558

Fran DeSena (973) 517-3132

To view the original version on PR Newswire, visit:

SOURCE Allergan plc

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store